Activation of a Yap1-mesenchymal-like program in β-cells during diabetes
7 affiliations
- 1Department of Medicine, Division of Endocrinology, Columbia University, New York, NY, USA
- 2Naomi Berrie Diabetes Center, Columbia University, New York, NY, USA
- 3Department of Medicine, Division of Digestive Diseases, Emory University, Atlanta, GA, USA
- 4Present address: Department of Medicine, Division of Digestive Diseases, Emory University, Atlanta, GA, USA
- 5Lead contact
- 6Present address: Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Weill Center for Metabolic Health, Weill Cornell Medicine, New York, NY, USA
- 7Forkhead BioTherapeutics, Inc., New York, NY, USA
Abstract
SUMMARY: A critical driver of type 2 diabetes is the failure of insulin-secreting β cells due to dysfunction and loss of cell number or identity. The signaling pathways that trigger these events remain unclear. Here, we identify an epithelial-to-mesenchymal (EMT)-like program that is activated in β cells to promote their loss with type 2 diabetes. This program is initiated in human and mouse β cells by the EMT transcription factor Yap1. While this protein is normally not present in β cells, Yap1 becomes upregulated in response to oxidative stress and impaired mitochondrial function. Chemical inhibition of Yap1 in islets reverses EMT-like activation while its overexpression in cells triggered the appearance of mesenchymal-like vimentin+ cells. Functionally, blocking Yap1 in isolated islets and in mice improves insulin secretion and alleviates diabetes. Taken together, we have identified a novel pathway of β-cell failure during type 2 diabetes, revealing a potential target for future diabetes treatment.
Related
- Single-cell dissection of shoulder-derived mesenchymal stem cells reveals source-specific progenitor heterogeneity and a SIX2-driven chondrogenic program.
- Early morphological and gene/protein expression dynamics of human synovial mesenchymal stem cells during adhesion to a damaged meniscal surface
- Gene amplification during differentiation of mesenchymal stem cells towards chondrocytes
- Immune Consequences of Endothelial Cells’ Activation and Dysfunction During Sepsis
- The systemic administration of multipotent mesenchymal stromal cells alters the inflammatory response in the lung during murine polymicrobial sepsis.
BibTeX
@article{mckimpson2026activation,
title = {{Activation of a Yap1-mesenchymal-like program in β-cells during diabetes}},
author = {Wendy M. McKimpson and Nehan Hoque and Matthew Barter and Jinsook Son and April Y. Lee and Hitoshi Watanabe},
journal = {Cell reports},
year = {2026},
month = jun,
doi = {10.1016/j.celrep.2026.117596},
url = {https://doi.org/10.1016/j.celrep.2026.117596},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Activation of a Yap1-mesenchymal-like program in β-cells during diabetes
AU - Wendy M. McKimpson
AU - Nehan Hoque
AU - Matthew Barter
AU - Jinsook Son
AU - April Y. Lee
AU - Hitoshi Watanabe
PY - 2026
DA - 2026/06/30
JO - Cell reports
DO - 10.1016/j.celrep.2026.117596
UR - https://doi.org/10.1016/j.celrep.2026.117596
AB - SUMMARY: A critical driver of type 2 diabetes is the failure of insulin-secreting β cells due to dysfunction and loss of cell number or identity. The signaling pathways that trigger these events remain unclear. Here, we identify an epithelial-to-mesenchymal (EMT)-like program that is activated in β cells to promote their loss with type 2 diabetes. This program is initiated in human and mouse β cells by the EMT transcription factor Yap1. While this protein is normally not present in β cells, Yap1 becomes upregulated in response to oxidative stress and impaired mitochondrial function. Chemical inhibition of Yap1 in islets reverses EMT-like activation while its overexpression in cells triggered the appearance of mesenchymal-like vimentin+ cells. Functionally, blocking Yap1 in isolated islets and in mice improves insulin secretion and alleviates diabetes. Taken together, we have identified a novel pathway of β-cell failure during type 2 diabetes, revealing a potential target for future diabetes treatment.
SN - 2211-1247
ER -